Reference health
The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
52/52 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 52 checked references that resolve
resolves10.1126/science.3012781
The Product of the Human c-
<i>erb</i>
B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity
resolves10.1093/annonc/mdn169
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
resolves10.7314/APJCP.2014.15.13.5343
Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer
resolves10.1080/15384047.2015.1056415
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
resolves10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
resolves10.1038/bjc.2014.18
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
resolves10.1007/s00280-015-2807-7
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy
resolves10.1007/s00280-015-2881-x
Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
resolves10.3748/wjg.v17.i11.1501
Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma
resolves10.1007/s10120-013-0239-9
Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population
resolves10.1007/s10120-014-0430-7
Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer
resolves10.1007/s10120-015-0576-y
Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
resolves10.1007/s10654-010-9491-z
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
resolves10.1053/paor.1999.0171
Expression of c-erbB-2 Oncoprotein in Gastric Carcinoma: Correlation with Histopathologic Characteristics and Analysis of Ki-67
resolves10.4143/crt.2004.36.4.240
Prognostic Significance of Immunohistochemical Expression of EGFR and C-erbB-2 Oncoprotein in Curatively Resected Gastric Cancer
resolves10.1093/annonc/mdi064
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
resolves10.1007/s10620-005-9057-1
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
resolves10.1016/j.humpath.2007.02.005
Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction
resolves10.1007/s00268-009-0142-z
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
resolves10.1155/2011/391564
HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain
resolves10.1245/s10434-011-1695-2
Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays
resolves10.1007/s12664-012-0217-x
HER2 as a therapeutic target in the gastric cancer: is it sufficient?
resolves10.1245/s10434-012-2818-0
A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages
resolves10.3748/wjg.v18.i19.2402
Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis
resolves10.1093/annonc/mds104
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
resolves10.1097/PAI.0b013e31821c821c
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
resolves10.1186/1477-7819-10-274
Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial
resolves10.1007/s00595-013-0544-2
Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy
resolves10.1007/s12094-012-0921-0
Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer
resolves10.3748/wjg.v19.i21.3316
Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population
resolves10.1007/s12253-013-9654-9
HER2 in Gastric Cancer: An Immunohistochemical Study on Tissue Microarrays and the Coressponding Whole-Tissue Sections with a Supplemental Fish Study
resolves10.3748/wjg.v19.i14.2171
Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer
resolves10.1186/1746-1596-8-76
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
resolves10.1007/s10147-013-0542-9
Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer
resolves10.1186/1471-2407-14-823
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients
resolves10.5230/jgc.2014.14.3.180
Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection
resolves10.1016/j.clinre.2014.06.019
HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis
resolves10.1007/s13277-014-2933-6
TFF3 and HER2 expression and their correlation with survival in gastric cancer
resolves10.1136/jclinpath-2014-202657
Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival
resolves10.1186/s12876-015-0384-1
Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
resolves10.3892/ol.2015.3609
A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients
resolves10.7314/APJCP.2015.16.17.7755
Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma
resolves10.1007/s10120-014-0398-3
HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial)
resolves10.5301/tj.5000444
Impact of c-erbB-2 Protein on 5-year Survival Rate of Gastric Cancer Patients after Surgery: A Cohort Study and Meta-analysis
resolves10.1158/1078-0432.CCR-12-1318
Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
resolves10.1111/j.1365-2559.2008.03028.x
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
resolves10.1016/j.bbamcr.2006.10.001
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
resolves10.1016/j.ccr.2009.03.020
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
resolves10.1158/1078-0432.CCR-0951-3
Association between HER-2/<b>
<i>neu</i>
</b> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients
The 6 references without a DOI — listed, not checked
no DOI — not checkedYi JH, Kang JH, Hwang IG, et al. A retrospective analysis for patients with HER2 positive gastric cancer who were treated with trastuzumab-based chemotherapy: in the perspectives of ethnicity and histology. Cancer Res Treat. 2015;48(2):553–60.
no DOI — not checkedTang D, Liu CY, Shen D, et al. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther. 2015;8:7–14.
no DOI — not checkedIsmail HM, Moneer M, El-baradie M, et al. Clinicopathologic and prognostic significance of overexpression of Her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. J Egypt Natl Canc Inst. 2007;19(2):147–57.
no DOI — not checkedAnsari J, Chehrei A, Amini M, et al. The prognostic significance of Her2-Neu overexpression in gastric carcinomas. Iran J Cancer Prev. 2011;4:170–6.
no DOI — not checkedChan DS, Campbell F, Edwards P, et al. Relative prognostic value of human epidermal growth factor receptor 2 (HER2) expression in operable oesophagogastric cancer. ISRN Surg. 2012;2012:804891.
no DOI — not checkedRajagopal I, Niveditha SR, Sahadev R, et al. HER 2 expression in gastric and gastro-esophageal junction (GEJ) adenocarcinomas. J Clin Diagn Res. 2015;9(3):EC06–10.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1186/s12957-017-1132-5"><img src="https://citestamp.com/citestamped/10.1186/s12957-017-1132-5/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1186/s12957-017-1132-5)